ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Atrophic Acne Scars Clinical Trial

Official title:

An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05995340
• Other study ID #: 2015-702-008
• Secondary ID: CIV-23-03-042622
• Status: Recruiting
• Phase: Phase 3
• Start date: November 21, 2023
• Est. completion date: August 18, 2025

Study information

• Verified date: June 2024
• Source: AbbVie
• Contact: ABBVIE CALL CENTER
• Phone: 844-663-3742
• Email: abbvieclinicaltrials[@]abbvie.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars.

ELAPR002f Injectable Gel is an investigational device being developed for the treatment of facial atrophic acne scars. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline control group. Around 156 adult participants with moderate to severe atrophic acne scarring on both cheeks will be enrolled in the study in approximately 12 sites in Germany and Canada.

Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline control and will be followed for up to an additional 12 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 156
• Est. completion date: August 18, 2025
• Est. primary completion date: August 18, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants in general good health, with no active COVID-19 infection, and seeking improvement of atrophic acne scars.

• Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan ASIS) on each cheek based on Evaluating Investigator's live assessment (both cheeks must qualify but do not need to have the same score) at the first screening visit.

• At least 5 rolling or boxcar-type acne scars in total within the predefined assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator.

Exclusion Criteria:

• The participant has active/ongoing acne lesions on the face.

• Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face.

• The participant presents with predominantly ice pick scars.

• History of keloid scar formation, hypertrophic scarring and/or post inflammatory hyperpigmentation or hypopigmentation.

• History of granulomatous or connective tissue disease.

• Diagnosed autoimmune disease (eg, Type 1 diabetes, rheumatoid arthritis, scleroderma, vitiligo).

• Diagnosed history of asthma.

• Known hypersensitivity to the constituents of the device.

• Visual acuity of 20/100 or worse or abnormal confrontational visual fields or ocular motility.

Related Conditions & MeSH terms

• Atrophic Acne Scars
• Atrophy

Intervention

Device:
• ELAPR002f Injectable Gel
Intradermal Injections

Other:
• Saline Control
Intradermal Injections

Locations

Country	Name	City	State
Canada	Dermetics Cosmetic Dermatology /ID# 227469	Burlington	Ontario
Canada	Alberta DermaSurgery Centre /ID# 243168	Edmonton	Alberta
Canada	The Centre for Clinical Trials /ID# 233841	Oakville	Ontario
Canada	The Center For Dermatology /ID# 227470	Richmond Hill	Ontario
Canada	Humphrey & Beleznay Cosmetic Dermatology /ID# 266634	Vancouver	British Columbia
Canada	Pacific Derm /ID# 227467	Vancouver	British Columbia
Canada	Bertucci MedSpa Inc. /ID# 227468	Woodbridge	Ontario
Germany	Dermatologische Gemeinschaftspraxis Mahlow /ID# 262566	Blankenfelde-Mahlow	Brandenburg
Germany	Rosenpark Research /ID# 227471	Darmstadt	Hessen
Germany	Privatpraxis Dr. Hilton & Partner /ID# 227472	Duesseldorf	Nordrhein-Westfalen
Germany	Hautok and Hautok-cosmetics /ID# 227474	Muenchen
Germany	MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 227475	Oberursel

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Countries where clinical trial is conducted

Canada,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change from Baseline in Acne Scar Area	The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).	Baseline to Day 181
Primary	Number of Participants with Adverse Events	An AE is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. This definition includes events related to the investigational medical device or comparator and events related to the procedures involved.	Up to Day 420
Primary	Number of Participants with Presence of Binding Antibodies	Presence of binding antibodies	Up to Day 420
Primary	Number of Participants with Injection Site Responses (ISRs) and Systemic Responses	Incidence of ISRs/systemic responses as recorded by e-diary for up to 30 consecutive days after each of the 3 treatment sessions starting on the day of injection. ISRs are defined as redness, pain after injection, tenderness to touch, firmness, swelling, lumps/bumps, bruising, itching and discoloration (not redness or bruising).	Up to Day 420
Primary	Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters	Vital sign parameters include body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.	Up to Day 420
Primary	Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters	Clinical laboratory parameters include tests of hematology, chemistry, urinalysis and prolactin. The investigator will assess the results for clinical significance.	Up to Day 420
Primary	Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements	Physical measurements include weight and BMI. The investigator will assess the results for clinical significance.	Up to Day 420
Primary	Change from Baseline Procedure Pain	Participants will assess procedure pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) after each of the 3 treatment sessions.	Up to Day 61
Primary	Number of Participants with a Positive Skin Test	Participants will undergo a skin test in the volar area of the forearm to test for hypersensitivity.	Up to Day 30
Primary	Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion	Number of participants with any acute cognitive changes or any change in confrontational visual fields, ocular motility, or a worsening (1-line change or more) on the Snellen visual acuity assessment,	Up to Day 420
Secondary	Change from Baseline on the Overall Score of ACNE-Q Acne Scars Questionnaire	The ACNE-Q Acne Scars questionnaire includes 10 questions that ask how much the participant is bothered by their acne scars on a 4-point scale ranging from 1=Not at all to 4=Very Much.	Up to Day 420
Secondary	Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress	ACNE-Q - Appearance-Related Distress questionnaire includes 8 questions that ask about how the participants describe themselves on a 4-point scale ranging from 1=Never to 4=Always.	Up to Day 420
Secondary	Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin	FACE-Q Satisfaction With Skin questionnaire includes 12 questions that ask how much the participants are satisfied or dissatisfied with their facial skin on a 4-point scale ranging from 1=Very Dissatisfied to 4=Very Satisfied.	Up to Day 420
Secondary	Percentage of Participants Achieving "Responder" Status on Either Cheek Based on the Allergan Acne Scar Improvement Scale (ASIS), as assessed by the Evaluating Investigator	A "responder" is a participant who achieves 1-grade improvement on either cheek based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately.	Up to Day 420
Secondary	Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area	The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the TI.	Up to Day 420
Secondary	Percent Change from Baseline in Acne Scar Area	The acne scar area is measured by 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the TI.	Up to Day 420
Secondary	Percent Change from Baseline in Acne Scar Volume	The acne scar volume is measured by 3D camera imaging software. Volume is defined as the sum of the individual scar volume of the 5 most prominent scars identified by the TI.	Up to Day 420

External Links

•   Related Info